TABLE 1.

Comparison of Characteristics of Patients With and Without Discordant Paired Activated Partial Thromboplastin Time/Anti-Factor-Xa

Variables	Overall, n = 32	No Discordant aPTT/Anti-Xa, n = 8	At Least One Discordant aPTT/Anti-Xa, n = 24	p
Age, yr	38 (26.8–57.8)	39.50 (26.3–47)	38 (27.5–61.5)	0.45
Gender, male	24 (75)	6 (75)	18 (75)	1
Weight, kg	79 (69.8–85.3)	62.5 (53.8–76.3)	80 (74.3–86)	0.03
Acute Physiology and Chronic Health Evaluation III score	57.5 (45.5–88.3)	59 (54.5–68)	55.5 (43.3–90)	0.56
Proportion of patients randomized in:				0.04
“Low-dose heparin” group	16 (50)	7 (87.5)	9 (37.5)
“Therapeutic anticoagulation” group	16 (50)	1 (12.5)	15 (62.5)
Comorbidities
Immunosuppressed	4 (12.5)	1 (12.5)	3 (12.5)	1
Respiratory failure	3 (9.4)	3 (37.5)	0 (0)	0.01
Cardiovascular disease	5 (15.6)	0 (0)	5 (20.8)	0.3
Renal failure	1 (3.1)	1 (12.5)	0 (0)	0.25
Insulin dependent diabetes	1 (3.1)	0 (0)	1 (4.2)	1
Ongoing sepsis before ECMO	15 (46.9)	3 (37.5)	12 (50)	0.69
Heparin dose (U/d)	20,476 (11,176–29,904)	9,340 (7,450–11,500)	22,241 (13,936–31,445)	0.008
ECMO type
Venovenous ECMO	23 (71.9)	7 (87.5)	16 (66.7)	0.39
Venoarterial ECMO	9 (28.1)	1 (12.5)	8 (33.3)	0.39
Indications for venovenous ECMO				0.07
Asthma	2 (6.2)	1 (12.5)	1 (4.2)
Bacterial or viral pneumonia	9 (28.1)	2 (25)	7 (29.1)
Lung transplantation	3 (9.3)	3 (37.5)	0 (0)
Other respiratory disorders	9 (28.1)	1 (12.5)	8 (33.3)
Indications for venoarterial ECMO				0.51
Acute cardiomyopathy	2 (6.2)	0 (0)	2 (8.3)
Acute myocardial infarction	1 (3.1)	0 (0)	1 (4.2)
Heart transplantation	3 (9.4)	0 (0)	3 (12.5)
Myocarditis	1 (3.1)	1 (12.5)	0 (0)
Other	2 (6.2)	0 (0)	2 (8.3)
Days on ECMO	8 (5.5–14)	6 (2.8–8.3)	10 (7–16)	0.03

anti-Xa = anti-factor-Xa, aPTT = activated partial thromboplastin time, ECMO = extracorporeal membrane oxygenation.

Continuous variables are expressed as median (interquartile range) and categorical variables are expressed as percentage.